The BrainSense Adaptive technology is an enhancement to Medtronic’s Percept DBS neurostimulators. The advancement personalizes therapy based on a patient’s brain activity in real-time. Therapy ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever ...

Medtronic said the Food and Drug Administration approved a brain stimulation system for people afflicted with Parkinson's disease.

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...

Medtronic's FDA-approved BrainSense Adaptive DBS system revolutionizes Parkinson's therapy with real-time adjustments for ...

The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...

A higher dividend yield is nice because it allows you to collect more dividend income on every dollar you invest in a stock.

A hospital trust has become the first in the UK to fit patients with a new leadless pacemaker. Northampton General Hospital ...